A team committed to the development of a therapeutic portfolio in hearing loss

WHO ARE WE ?

Sensorion is a pioneering clinical-stage biotech company, dedicated to the development of innovative therapies to restore, treat and prevent within the field of hearing loss

Nawal Ouzren

CEO and Director
  • 15 years in pharmaceutical operations and strategic management
  • Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
  • Formerly Group Vice President, Rare Genetic Diseases, Shire

Géraldine Honnet, M.D.

Chief Medical Officer
  • 20 years in clinical development and gene therapy
  • Formerly Director of Development, Genethon and Medical Director, Parexel International
  • Previously Senior Clinical Manager, Transgene

Bernd Schmidt

Chief Technical Officer
  • 20 years’ experience in life sciences
  • CMC expert
  • Formerly Vice President Product Delivery at Quell Therapeutics and MPD Leader at GSK Stevenage

Laurene Danon

Chief Financial Officer
  • 15 years of experience in investment banking and international equity capital markets.
  • Formerly Senior Banker at Jefferies and J.P. Morgan

Stéphanie Filipe

Head of the Project Management Office
  • 15 years in therapeutic products development in Biotechs from bench to beside including gene and cell therapies
  • Formerly R&D Director at OTR3, Program Leader at Cellectis
  • Ph.D., Cellular Biology & Biochemistry

Laurent Désiré

Head of Preclinical Development
  • Over 15 years in pharmaceutical R&D and clinical development, especially in gene therapy and neuroscience
  • Formerly Head of Cellular and Molecular Biology unit at YposKesi, and R&D Executive Director at Diaxonhit and ExonHit
  • Ph.D., Biology of Aging

Christine Le Bec

Head of CMC Gene Therapy
  • 25 years in production process development for gene therapy
  • Formerly Head of CMC analytical department, Genethon
  • Ph.D., Biochemistry and Analytical Chemistry

Valérie Salentey

Director of Regulatory Affairs & Quality Assurance
  • Over 15 years in Regulatory Affairs and Quality Assurance in Biologics and advanced therapies
  • Formerly headed Regulatory Affairs at Cytheris, Généthon, PPD, Neovacs
  • Doctor of Pharmacy (PharmD)

Rachel Cooper

Head of Audiology
  • Over 23 years in the hearing health industry
  • Formerly Global Professional Marketing Manager at Cochlear Ltd.
  • Doctor of Audiology (AuD), Cochlear Implant Specialty Certification (CISC), Pediatric Audiology Specialty Certification (PASC), Executive MBA

Khalil Barrage

Interim Chairman of the Board
  • Director, Representative of Invus
  • 15 years of experience in portfolio management at The Olayan Group in New York
  • Managing Director for the Invus Group in New York and Board member of Protagenic and Celtaxsys

Nawal Ouzren

CEO and Director
  • 15 years in pharmaceutical operations and strategic management
  • Formerly VP and Head, Hemophilia Franchise, Baxalta (within Shire)
  • Formerly Group Vice President, Rare Genetic Diseases, Shire

Julien Miara

Director, Representative of Invus
  • 10 years of experience in investment, covering biotechnology among other sectors
  • Director at Invus

Cédric Moreau

Director representing Sofinnova Partners
  • 18 years of experience in investment banking and in life sciences
  • Partner in the Crossover investment team at Sofinnova Partners

Natalie Berner

Director representing Redmile Group
  • Managing Director specializing in therapeutic products at Redmile
  • Former Research Associate at New York University School of Medicine
  • Bachelor’s degree in Community Health from Brown University and Certificate in Premedical Sciences from Columbia University
  • Member of two other boards: Redx Pharma and BioInvent

Eric de la Fortelle

Independent Director
  • 10 years of experience as scientific researcher in biotechnology, CEO and member of several Boards
  • Venture Partner at Seventure Partners

John Furey

Independent Director
  • 20 years of experience as CEO and Chief Operating Officer in pharmaceutical societies
  • CEO of Imvax
  • Non Executive Director at Adaptimmune

Aniz Girach

Independent Director
  • M.D., over 22 years’ experience in the pharma industry
  • CMO at ProQR Therapeutics
  • Member of three Scientific Advisory Boards

Florian Reinaud

Board Observer Redmile Group
  • Special Advisor Europe for Redmile Group
  • 20 years experience in Healthcare Innovation and Capital Investment
  • Former emergency physician in the UK’s National Health Service
  • MD., awarded with Distinction from Imperial College London and holds a BA(hons) in Physiology from the University of Oxford
  • Board Member of Sensome

Federico Mingozzi, Ph.D.

Non-Executive Director
  • More than 25 years experience in gene therapy, immunology, as well as biochemistry and
    molecular biology
  • Previously Chief Science and Technology at Spark Therapeutics
  • He holds a bachelor’s degree in biology and a Ph.D. in biochemistry and molecular biology from the
    University of Ferrara in Italy, and a M.B.A. from Drexel University.

Pr Christine Petit

Chair of the Scientific Advisory Board
  • Chair of Genetics and Cellular Physiology,  Professor at College de France and at Institut Pasteur (Paris)
  • Head of the Laboratory of Genetics and Physiology of Hearing  at Institut Pasteur
  • Managing Director of the French Hearing Institute
  • Member of the French and American Sciences Academies  and the American Medical Academy

Pr Alain Fischer

  • Professor at College de France
  • Former director and founding member of the Institute for Genetic Diseases (Imagine)
  • Former director of the pediatric immuno-hematology department at Necker Hospital

Dr Robert Dow

  • More than 37 years of experience in the pharmaceutical and biotech industry
  • Former Chief Medical Officer at PPD Inc.
  • Substantial experience across therapeutic areas from pre-clinical to Phase 3 development

Pr Paul Avan

  • Physicist and Medical Doctor in Biophysics
  • Head of the Center for Research and Innovation in Human Audiology at Hearing Institute (Paris)
  • Designed original objective methods of exploration of the cochlea and auditory pathways

Dr. Diane Lazard

  • ENT Surgeon and former Head of Clinic at AP-HP
  • Principal Associate Investigator at the Hearing Institute (Paris)
  • Currently pursuing research on deciphering language processing variability in deafness

Dr. Hernán López-Schier

  • Senior Group Leader and Research Unit Director at the Helmholtz Center in Munich
  • Currently pursuing research on fundamental sensory biology and sensory dysfunction
  • His group was the first to visualize the regeneration of mechanosensory hair cells in their natural context